Raptor Pharmaceutical Corp.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Raptor Pharmaceutical Corp.
Most roads led to India in 2020 when it came to deals to expand access to COVID-19 therapies, but the challenging year also saw significant private equity interest and there are expectations of more action ahead in the new year.
BioIntelliSense is initiating a 2,500-participant virtual study to validate whether its BioSticker can be used for early detection of COVID-19.
Keeping Track: J&J Amivantamab, Infectious Disease Agents From Iterum, VBI And Atox Submitted; Another Furoscix CRL
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker
After a year like no other for the global medtech industry, 2021 will present a different set of market challenges for device and diagnostic companies.
- Site Specific
- Drug Delivery
- Large Molecule
- Other Names / Subsidiaries
- Encode Pharmaceuticals, Inc.
- TorreyPines Therapeutics, Inc. (Neurogenetics Inc.)